Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China.

BACKGROUND: Poor adherence to treatment is a problem in glaucoma, and patient dissatisfaction with topical glaucoma medication is a barrier to adherence. The objective of this study was to evaluate glaucoma patients' satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution (BTFC).
METHODS: This observational, multicenter study was conducted in China in adults with glaucoma treated with BTFC for 1-3 months. Five hundred patients answered a questionnaire concerning their demographic characteristics, history of glaucoma and topical glaucoma treatment, and use of BTFC. The primary endpoint was patient satisfaction with BTFC assessed on a 10-point scale (1= very dissatisfied, 10= very satisfied).
RESULTS: Patients received BTFC alone (65%) or with other treatments (35%), most commonly a carbonic anhydrase inhibitor. Most patients (87%) used BTFC as a replacement for other medication, usually a β-blocker or prostaglandin analog; 13% received BTFC as add-on treatment. Key reasons for initiating BTFC therapy were poor efficacy of previous treatment (72% of patients) and side effects of previous treatment (32% of patients). Most patients agreed or very much agreed that BTFC provided better control of intraocular pressure (85% of patients), had a simpler administration (87% of patients), and was associated with better tolerance and comfort (82% of patients) compared with their previous treatment. Mean satisfaction scores were significantly higher for BTFC than for previous treatments among all patients (7.8 versus 6.0; P<0.0001) and within patient subgroups based on demographic characteristics, pattern of BTFC use, and previous treatment.
CONCLUSION: Patients were highly satisfied with BTFC used alone or concomitantly with another topical medication. Patients previously treated with a β-blocker, prostaglandin analog, carbonic anhydrase inhibitor, α-adrenergic agonist, or combination of two medications were more satisfied with BTFC than with their previous treatment. Most reported that intraocular pressure control, tolerability, and ease of administration improved with BTFC.

Introduction

The goal of treatment in patients with glaucoma is to reduce intraocular pressure (IOP) and consequently lower the risk of visual field loss.1 Many topical medications that effectively lower IOP are available, including β-blockers, carbonic anhydrase inhibitors, prostaglandin analogs, sympathomimetics, and miotics.2 In China, the most commonly used topical IOP-lowering medications are β-blockers (eg, timolol), prostaglandin analogs (bimatoprost, latanoprost, and travoprost), the α-agonist brimonidine, the carbonic anhydrase inhibitor brinzolamide, and fixed combinations of a prostaglandin analog, brimonidine, or brinzolamide with timolol. However, poor adherence of glaucoma patients to topical IOP-lowering therapy is endemic. Patient surveys and studies using devices that measure drops dispensed from medication bottles have suggested that at least 20% of patients do not use their medication as prescribed.3–5 Furthermore, pharmacy claims data studies have suggested that patients have medication available for dosing on an average of only 56% (range, 37%–92%) of days in the year following the index prescription,4 and in one study, only 10% of patients had medication available for dosing each day of the year.6 Poor adherence remains a significant limiting factor in the management of glaucoma because it is associated with greater loss of the visual field.7,8

Barriers to adherence to topical glaucoma treatment are common and include difficulty in eye drop administration, dosing frequency, inconvenience, forgetfulness, side effects, lack of understanding of the disease, and medication cost.9–12 Furthermore, patients with glaucoma frequently have ocular surface disease, which can affect the tolerability of topical glaucoma medication.13 In a multicenter international study, ocular surface disease was reported to be present in 59.2% of glaucoma patients using topical IOP-lowering medication.14 It is understood that adherence is better when patients have no problems with their medication and are satisfied with their treatment. A survey study by Day et al15 demonstrated that glaucoma and ocular hypertensive patients’ satisfaction with the effectiveness, ease, and convenience of topical treatment was significantly associated with reduced reluctance of the patients to use the treatment. In another study, most patients with glaucoma expressed a preference for dosing with a single drop each day, and 20% of patients believed that this dosing schedule would improve adherence.16 These results suggest that simplifying the treatment regimen using effective IOP-lowering medication may improve patient satisfaction and adherence to treatment.

Fixed combinations of IOP-lowering medications reduce the inconvenience associated with administration of multiple drops each day and may improve adherence.17 The fixed combination of bimatoprost 0.03%/timolol 0.5% (BTFC; Ganfort®, Allergan plc, Dublin, Ireland) has been shown to be well tolerated and effective in lowering IOP in multiple clinical studies, including studies in Chinese patients with glaucoma or ocular hypertension.18–21 However, patient satisfaction with BTFC treatment has not been fully explored. The primary objective of the present study was to assess glaucoma patients’ satisfaction with BTFC and with the efficacy, tolerability, and ease of use of BTFC in clinical practice in China.

Methods

This observational, multicenter, survey study was conducted from July 2015 to November 2015 at 20 sites in eight cities in China (Beijing, Shanghai, Guangzhou, Hangzhou, Nanjing, Changsha, Fuzhou, and Chengdu). All study procedures were in accordance with the Helsinki Declaration of 1975, as revised in 2000. The study was exempt from approval by the local ethics committees because it involved a survey procedure only, with adult participants, and no personally identifiable data were collected. There was no potential harm or risk to the participants. The participants’ responses were confidential, and the nature of the survey was such that if there were a breach, the disclosure of participants’ responses would not place the participants at risk of criminal or civil liability or be damaging to the participants’ financial standing, employability, or reputation. There were no negative repercussions for patients who chose not to participate. Patients were informed of the objective of the study, that their participation was voluntary, and that their responses would remain anonymous and confidential. They were also informed that they could withdraw from participation at any time and for any reason. Patients who completed the survey after being so informed were deemed to have provided informed consent.

A participating physician at the site introduced patients who were potentially eligible for the study to an investigator who then screened them for eligibility. Any adult outpatient diagnosed with glaucoma who had been using BTFC for 1–3 months was eligible. An upper limit of 3 months’ use was chosen to avoid bias, because we wanted to compare patients’ satisfaction with BTFC versus their previous treatment, and patients may better remember their satisfaction with a previous regimen when it was used within the past 3 months. The investigator administered a questionnaire to all eligible patients who agreed to participate. There were eight investigators (one per site), and all of the surveys at a site were administered by the same investigator. The investigator read the survey questions aloud and recorded the patient’s answers, because we anticipated that some of the patients would have very poor vision due to advanced glaucoma and would be unable to read and respond to a written survey. The questions were designed with simple wording to make them easily understandable and minimize any ambiguity. All of the investigators were trained to present the survey in a standard and objective manner. The questionnaire took approximately 10 minutes to complete. Data collected included patient demographics (gender, age, employment status, insurance status, household income), history of glaucoma, previous use of glaucoma treatment, duration and patterns of use of BTFC, reasons for the treatment change to BTFC, patient overall satisfaction with BTFC, and patient satisfaction with the IOP control provided by BTFC, the tolerability of BTFC, and the ease of administration of BTFC compared with previous treatment. In the assessment of reasons for using BTFC, patients were asked to indicate “yes” or “no” to potential reasons including poor efficacy of previous medication(s), safety profile/side effect of previous medication(s), BTFC recommended by friends/family members/other patients, inconvenient administration of previous medication(s), patient’s desire to try BTFC, cost of previous medication(s), and physician’s recommendation. Patients were also encouraged to provide other reasons.

Patients rated their overall satisfaction with BTFC and their overall satisfaction with their previous treatment on a 10-point scale from 1= extremely dissatisfied to 10= extremely satisfied. To evaluate patient satisfaction with the efficacy, tolerability, and ease of administration of BTFC, patients were asked whether they very much agreed, agreed, neither agreed nor disagreed, disagreed, or very much disagreed with the following statements: 1) BTFC provides better control of IOP compared with previous treatment; 2) BTFC has characteristics of better tolerability and comfort compared with previous treatment; and 3) administration of BTFC is simpler compared with previous treatment.

All statistical analyses were performed using SAS software (SAS Institute Inc, Cary, NC, USA). Between-group comparisons of mean satisfaction scores used independent samples t-tests; within-group comparisons used paired t-tests. The planned sample size was 500 patients.

Results

Patients were recruited at 20 investigational sites. Of the patients who were screened as potential candidates for the survey, approximately 70% met the criteria for participation in the study. Approximately 40% of eligible patients declined to participate, and 60% were administered the questionnaire.

A total of 500 patients with glaucoma from eight cities in China (56% from Tier 1 cities, 44% from Tier 2) completed the survey. Demographic characteristics of the patients are presented in Table 1. The mean age was 51 years, and 56.6% of the patients were female. Most patients either worked full time or were retired and had relatively good economic status (46.2% had a household income ≥60,000 RMB). Overall, 85% of the 500 respondents had medical insurance.

Table 1

Demographic characteristics

Parameter	Patients (N=500)
Male/female, n (%)	217 (43.4)/283 (56.6)
Age, mean (range), years	51 (18–95)
18–30 years, n (%)	43 (8.6)
31–40 years, n (%)	84 (16.8)
41–50 years, n (%)	121 (24.2)
51–60 years, n (%)	144 (28.8)
61–70 years, n (%)	74 (14.8)
>70 years, n (%)	34 (6.8)
Location, n (%)
Tier 1 city: Beijing, Guangzhou, or Shanghai	280 (56.0)
Tier 2 city: Changsha, Chengdu, Fuzhou,	220 (44.0)
Hangzhou, or Nanjing
Medical insurance coverage, n (%)
Yes	425 (85.0)
No	75 (15.0)
Employment status, n (%)
Full-time employment	212 (42.4)
Retired	212 (42.4)
Other	76 (15.2)
Annual household income (RMB), n (%)
0–34,999	80 (16.0)
35,000–44,999	68 (13.6)
45,000–59,999	97 (19.4)
≥60,000	231 (46.2)
Not reported	24 (4.8)

On average, the patients had been diagnosed with glaucoma 27 months previously and had used topical IOP-lowering drops for the previous 26 months (Table 2). All patients had begun IOP-lowering drops within 1 year of the diagnosis, and nearly 91% had initiated treatment immediately after diagnosis. Patients had been using BTFC for at least 1 month and no more than 3 months at the time of the survey; the majority (62.8%) had been using BTFC for 1–2 months (Table 2).

Table 2

Glaucoma and treatment history

Parameter	Patients (N=500)
Time since diagnosis of glaucoma
Mean, months	27
Range, years	0.25–20.2
Duration of topical IOP-lowering medication use
Mean, months	26
Range, years	0.33–20.3
Preexisting regimen before initiation of BTFC therapy, n (%)
Monotherapy
β-blocker	160 (32.0)
Prostaglandin analog	107 (21.4)
Carbonic anhydrase inhibitor	99 (19.8)
α-adrenergic agonist	61 (12.2)
Miotic	18 (3.6)
Combination therapy with two medications	55 (11.0)
Duration of treatment with BTFC, n (%)
1 month	43 (8.8)
>1–2 months	314 (62.8)
>2–3 months	143 (28.6)

Abbreviations: BTFC, bimatoprost/timolol fixed combination; IOP, intraocular pressure.

BTFC was used alone by 65% of patients; the other 35% of patients used BTFC in a regimen that included other topical IOP-lowering medication, most commonly a carbonic anhydrase inhibitor (14.2% of patients, Table 3). A significant number of patients (9.4%) used BTFC as adjunctive therapy with a prostaglandin analog (usually latanoprost or travoprost), 5.0% of patients used BTFC with a β-blocker, and 4.6% of patients used BTFC with an α-adrenergic agonist. Only four patients (0.8%) used BTFC in a multiple-drug regimen that included two or more other medications (Table 3).

Table 3

Pattern of BTFC use

Treatment pattern	Patients (N=500)
BTFC used alone, n (%)	328 (65.6)
BTFC used with concomitant therapy, n (%)	172 (34.4)
Carbonic anhydrase inhibitor	71 (14.2)
Prostaglandin analog	47 (9.4)
β-blocker	25 (5.0)
α-adrenergic agonist	23 (4.6)
Miotic	2 (0.4)
Carbonic anhydrase inhibitor plus α-adrenergic agonist	1 (0.2)
Carbonic anhydrase inhibitor plus β-blocker	2 (0.4)
Carbonic anhydrase inhibitor plus prostaglandin analog	1 (0.2)
BTFC replaced other medication in preexisting regimen, n (%)a	435 (87.0)
Replaced β-blocker	161 (32.2)
Replaced prostaglandin analog	104 (20.8)
Replaced carbonic anhydrase inhibitor	65 (13.0)
Replaced α-adrenergic agonist	57 (11.4)
Replaced miotic	18 (3.6)
Replaced two medications	30 (6.0)
BTFC added to preexisting regimen, n (%)	65 (13.0)
Added to carbonic anhydrase inhibitor	36 (7.2)
Added to α-adrenergic agonist	10 (2.0)
Added to prostaglandin analog	8 (1.6)
Added to β-blocker	6 (1.2)
Added to miotic	1 (0.2)
Added to two medications	4 (0.8)

Note:

Patients who used BTFC in replacement of one or two medications may have had other ongoing medication.

Abbreviation: BTFC, bimatoprost/timolol fixed combination.

For 87% of patients, BTFC replaced some or all of the medication(s) used in their preexisting regimen: 32.2% of patients replaced a β-blocker with BTFC, and 20.8% replaced a prostaglandin analog with BTFC (Table 3). For 13% of patients, BTFC was added to the preexisting regimen. The most common reason for initiating BTFC therapy was poor efficacy of the previous treatment (67.2% of patients, Table 4). Other common reasons were side effects of the previous treatment (30.8% of patients), recommendations from friends, family, or other patients (31.0% of patients), and inconvenient administration of the previous treatment (20.0% of patients).

Table 4

Reasons for initiating BTFC therapy

Reason, n (%)a	Total patient population (N=500)	Subgroup based on previous regimen
		β-blocker (N=160)	Prostaglandin analog (N=107)	Carbonic anhydrase inhibitor (N=99)	α-adrenergic agonist (N=61)	Miotic (N=18)	Two drugs (N=55)
Poor efficacy of previous medication(s)b	336 (67.2)	110 (68.8)	65 (60.7)	71 (71.1)	61 (100)	18 (100)	37 (67.3)
Safety profile/side effect of previous medication(s)b	154 (30.8)	50 (31.3)	31 (29.0)	23 (23.2)	16 (26.2)	12 (66.7)	22 (40.0)
BTFC recommended by friend/family/other patientb	155 (31.0)	63 (39.4)	32 (29.9)	24 (24.2)	16 (26.2)	4 (22.2)	16 (29.1)
Inconvenient administration of previous medication(s)b	100 (20.0)	44 (27.5)	21 (19.6)	8 (8.1)	14 (23.0)	2 (11.1)	11 (20.0)
Patient’s desire to try BTFCb	90 (18.0)	39 (24.4)	13 (12.1)	16 (16.2)	12 (19.7)	4 (22.2)	6 (10.9)
Cost of previous medication(s)b	29 (5.8)	8 (5.0)	14 (13.1)	1 (1.0)	2 (3.3)	0 (0)	4 (7.3)
Physician recommendationb	13 (2.6)	6 (3.8)	5 (4.7)	1 (1.0)	0 (0)	0 (0)	1 (1.8)
Better control of IOP with BTFCc	20 (4.0)	9 (5.6)	1 (0.9)	4 (4.0)	3 (4.9)	1 (5.6)	2 (3.6)
Simple administration of BTFCc	11 (2.2)	5 (3.1)	1 (0.9)	4 (4.0)	1 (1.6)	1 (5.6)	2 (3.6)
Fewer side effects with BTFCc	12 (2.4)	8 (5.0)	0 (0)	3 (3.0)	0 (0)	0 (0)	1 (1.8)
BTFC used before or after surgeryc	4 (0.8)	1 (0.6)	1 (0.9)	1 (1.0)	1 (1.6)	0 (0)	0 (0)
BTFC used for consolidationc	1 (0.2)	1 (0.6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Notes:

Patients could provide more than one reason for initiating BTFC treatment.

Selected response.

Volunteered response.

Abbreviations: BTFC, bimatoprost/timolol fixed combination; IOP, intraocular pressure.

Patients reported greater satisfaction with BTFC than with their previous treatment. Mean (± standard deviation, SD) satisfaction scores in the total patient population were 7.8±1.6 for BTFC versus 6.0±1.5 for previous treatment (P<0.0001, Table 5). Patient satisfaction scores for BTFC were also significantly higher than for previous treatment in patient subgroups defined by the pattern of BTFC use (used alone or with at least one other drug, and used as replacement or add-on therapy), previous treatment, reasons for changing treatment, and duration of BTFC treatment (Table 5), as well as in patient subgroups defined by gender, age, insurance coverage, employment status, and household income (Table 6).

Table 5

Mean BTFC and previous treatment satisfaction scores in all patients and subgroups based on treatment parameters

Patient group	N	Mean satisfaction score (SD)		P-valuea
		BTFC	Previous treatment
Total patient population	500	7.8 (1.6)	6.0 (1.5)	<0.0001
Subgroups by pattern of BTFC use
Treated with BTFC alone	325	7.9 (1.4)	6.0 (1.5)	<0.0001
Treated with BTFC and other therapy	175	7.6 (1.9)	6.2 (1.5)	<0.0001
BTFC replaced other drug(s)	435	8.0 (1.4)	6.0 (1.5)	<0.0001
BTFC added to previous treatment	65	6.8 (2.3)	6.3 (1.8)	0.0433
Subgroups by previous treatment
β-blocker	160	7.9 (1.2)	5.8 (1.3)	<0.0001
Prostaglandin analog	107	8.1 (1.4)	6.2 (1.5)	<0.0001
Carbonic anhydrase inhibitor	99	7.5 (1.6)	6.0 (1.6)	<0.0001
α-adrenergic agonist	61	7.7 (1.9)	6.1 (1.6)	<0.0001
Miotic	18	9.1 (1.5)	6.5 (1.4)	<0.0001
Two drugs	55	7.3 (2.1)	6.3 (1.5)	0.0051
Subgroups by reason for initiating BTFC
Poor efficacy of previous treatment	336	7.7 (1.7)	6.0 (1.5)	<0.0001
Side effect of previous treatment	154	7.8 (1.6)	5.9 (1.5)	<0.0001
BTFC recommended by friend/family/other patient	155	8.0 (1.3)	6.0 (1.3)	<0.0001
Inconvenient administration of previous treatment	100	7.9 (1.4)	5.8 (1.3)	<0.0001
Patient desire to try BTFC	90	8.2 (1.2)	6.1 (1.4)	<0.0001
Subgroups by duration of BTFC treatment
1 month	43	7.5 (1.4)	5.8 (1.5)	<0.0001
>1–2 months	314	7.8 (1.7)	5.9 (1.5)	<0.0001
>2–3 months	143	7.9 (1.6)	6.4 (1.6)	<0.0001

Note:

The P-value for comparison between BTFC and previous treatment (paired t-test).

Abbreviations: BTFC, fixed-combination bimatoprost/timolol; SD, standard deviation.

Table 6

Mean BTFC and previous treatment satisfaction scores in patient subgroups based on demographics

Demographic parameter	Patient subgroup	N	Mean satisfaction score (SD)		P-valuea
			BTFC	Previous treatment
Gender	Male	217	8.0 (1.6)	6.0 (1.4)	<0.0001
	Female	283	7.7 (1.6)	6.1 (1.5)	<0.0001
Age	18–30 years	43	7.1 (1.8)	5.4 (1.7)	<0.0001
	31–40 years	84	7.8 (1.8)	6.2 (1.6)	<0.0001
	41–50 years	121	7.9 (1.6)	6.2 (1.4)	<0.0001
	51–60 years	144	7.8 (1.5)	6.0 (1.4)	<0.0001
	61–70 years	74	8.2 (1.3)	6.1 (1.6)	<0.0001
	>70 years	34	7.7 (1.6)	6.2 (1.4)	<0.0001
Medical insurance coverage	Yes	425	7.9 (1.6)	6.1 (1.4)	<0.0011
	No	75	7.4 (1.8)	5.7 (1.8)	<0.0011
Employment	Full-time worker	212	7.8 (1.7)	6.1 (1.5)	<0.0001
	Retired	212	7.9 (1.4)	6.1 (1.4)	<0.0001
	Other	76	7.5 (1.8)	5.7 (1.6)	<0.0001
Annual household income (RMB)	<14,000	19	8.1 (1.8)	7.0 (1.5)	0.0481
	14,001–19,999	10	8.1 (1.1)	5.3 (1.0)	<0.0001
	20,000–24,999	14	7.8 (1.8)	5.7 (1.1)	0.0009
	25,000–34,999	37	7.8 (1.6)	6.1 (1.6)	<0.0001
	35,000–44,999	68	7.6 (1.8)	5.9 (1.4)	<0.0001
	45,000–59,999	97	7.9 (1.5)	6.0 (1.5)	<0.0001
	≥60,000	231	7.9 (1.5)	6.2 (1.4)	<0.0001
	Unknown	24	7.3 (2.3)	5.3 (1.8)	0.0002

Note:

The P-value for comparison between BTFC and previous treatment (paired t-test).

Abbreviations: BTFC, fixed-combination bimatoprost/timolol; SD, standard deviation.

The level of patient satisfaction with BTFC was higher in patients who used BTFC as a replacement for other medication than in those who added it to previous treatment (mean ± SD scores of 8.0±1.4 versus 6.8±2.3, P<0.0001). Similarly, the level of patient satisfaction with BTFC was higher in patients previously treated with a prostaglandin analog than in those previously treated with a carbonic anhydrase inhibitor (P=0.0004) or a combination of two drugs (P=0.0008) (mean ± SD scores of 8.1±1.4, 7.5±1.6, and 7.3±2.1, respectively). The mean score of patient satisfaction with BTFC was 7.1 in patients aged 18–30 years and ranged from 7.8–8.2 in patients aged 41–70 years (Table 6).

Most patients agreed or very much agreed with statements that BTFC could provide better control of IOP, was simpler to administer, and had characteristics of better tolerance and comfort compared with their previous treatment (Figure 1).

Figure 1

Percentage of patients who agreed or strongly agreed with statements regarding IOP control, ease of use, and tolerability of BTFC compared with previous treatment.

Abbreviations: BTFC, bimatoprost/timolol fixed combination; IOP, intraocular pressure.

Discussion

The glaucoma patients in urban China who were surveyed in this study were highly satisfied with BTFC treatment, as shown by their mean satisfaction score of 7.8 for BTFC compared with 6.0 for previous treatment. Most patients (87%) replaced other medication with BTFC, while 13% added BTFC to a preexisting regimen. The most common reasons for switching to or adding BTFC were poor efficacy of the previous treatment and side effects of the previous treatment. This suggests that both efficacy and tolerability are important motivators for changes in glaucoma treatment regimens in China.

In the current study, most patients reported that BTFC provided better control of IOP, had a simpler administration, and was associated with better tolerance and comfort than their previous therapy. Evidence in the literature suggests that efficacy, ease of use, and tolerability were factors that likely contributed to patients’ high level of satisfaction with BTFC.15,22 In a study by Day et al15 in patients with glaucoma or ocular hypertension, patient satisfaction with treatment was significantly correlated with the perceived effectiveness of the medication, the ease and convenience of its use, and lack of side effects (all P<0.001). In a more recent study in patients with glaucoma and ocular hypertension, Kerr et al22 found that satisfaction with the frequency of eye drop use, the convenience of use, and the ease of administration were all predictive of patient satisfaction with topical treatment (all P<0.001).

Switching between topical IOP-lowering medications is common in long-term glaucoma therapy. In this study, switching from other medication to BTFC was associated with greater patient satisfaction than adding BTFC to the preexisting regimen. These results are consistent with a previous study showing that patients with glaucoma or ocular hypertension who were prescribed one medication were more satisfied with treatment than patients who were prescribed multiple medications.15 Minimizing the number of medications used may improve patient satisfaction both by increasing treatment convenience and by reducing ocular exposure to drugs and preservatives, which may improve ocular tolerability. The once-daily dosing schedule used with BTFC is also considered by patients to be more convenient than multiple daily doses15,22,23 and may be preferred by patients,16 leading to higher patient satisfaction.

The majority of patients (80%) reported using BTFC alone or with a concomitant carbonic anhydrase inhibitor. Unexpectedly, however, approximately 14% of patients reported using BTFC with a concomitant prostaglandin analog or β-blocker. Almost all of these patients were seen at a single hospital in a province in southern China. This finding suggests that current recommended glaucoma treatment strategies are not used consistently throughout China, and there is a need to improve glaucoma therapy and standardize appropriate use of IOP-lowering medications in China.

A limitation of the study is that the survey was read to the patients, and although the investigators were trained to read the questions in an objective manner that would not influence patient responses, it is possible that responses might have differed if the patients had been given a written survey. Another limitation of this study is that patients were required to have used BTFC for a period of 1–3 months. No patients who stopped using BTFC within 1 month after beginning treatment completed the survey. Therefore, a patient selection bias could have affected mean satisfaction scores, if patients who were dissatisfied stopped using BTFC within the first month after treatment initiation. Also, the satisfaction of patients with BTFC after long-term use was not evaluated.

Conclusion

The results of this study demonstrate that glaucoma patients in China were more satisfied with BTFC than with their previous regimen of a β-blocker, prostaglandin analog, carbonic anhydrase inhibitor, α-adrenergic agonist, miotic, or two medications used concomitantly. More than 80% of patients agreed or very much agreed that BTFC was associated with improvements in IOP control, tolerability, and ease of administration compared with their previous treatment. The high levels of patient satisfaction with BTFC compared with previous treatment may lead to improved adherence to therapy, and ultimately, better visual outcomes. Additional studies of patient satisfaction with longer-term use of BTFC are warranted.